Industry Fears Realized As Japan Moves To Annual Price Cuts
Against the protests of the innovative pharma industry, Japan is pushing ahead with an overhaul of its drug reimbursement pricing system that will include a shift to annual price revisions.
You may also be interested in...
Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
With policy surrounding the regular drug price revision in Japan next month finalized and a list of new tariff prices just released, it has become clear that Gilead is facing sizeable reimbursement reductions for its two big-selling hepatitis C drugs in the country.